DKSH (DKSH) Jefferies Global Healthcare Conference summary
Event summary combining transcript, slides, and related documents.
Jefferies Global Healthcare Conference summary
17 Nov, 2026Industry shifts and partnership model
Emerging biopharma accounts for 60% of the pipeline; China contributes more than 30% of the global pipeline, including first-in-class innovation.
The largest pharma patent cliff in history is expected over the next 3 years; MFN pressure and geopolitics are reshaping profitability and launch sequencing.
Three-quarters of industry value is concentrated in the top 10 markets; outsourcing is growing as pharma scales back direct presence in long-tail markets and biotech seeks scaled commercialization partners.
Partner expectations are shifting from distribution to regional and global integrated platforms focused on specialty and rare disease, launch excellence, patient access, compliance, and beyond-the-pill services.
Platform ambition and capabilities
Ambition: become a leading global integrated healthcare platform serving patients across most of the world, with specialty and rare-disease capabilities and growth from in-licensing and own brands.
Healthcare net sales were CHF 5.8 billion last year, with reach across 17 Asia Pacific markets and more than 4,000 commercial associates; coverage excludes China, Japan, and India.
Medical affairs includes more than 70 associates; digital patient solutions serve more than 120,000 patients, with 30,000 active HCPs and nearly 300 specialty brands.
Coverage spans payer, prescriber, and frontier markets across Asia Pacific; therapeutic areas include oncology, hematology, immunology, neuroscience, rare disease, and others, reaching more than 75,000 physicians.
Launch planning starts 2.5–3 years ahead, combining medical engagement and access planning; post-approval execution focuses on message, customer, channel, and frequency.
Growth and geographic expansion
A Japanese specialty pharma outsourced its full portfolio in Q4 2024; a Singapore metabolic medicine launch overtook its competitor within 6 months.
Recent agreements include a U.S. biopharma launch portfolio in Hong Kong and Macau, pain launches in 8 APAC markets, and a rare cardiovascular medicine planned for Australia, Korea, Taiwan, and Singapore.
The recently announced NewBridge Pharma acquisition adds a presence in 14 Middle East and North Africa markets, with specialty and rare-disease capabilities.
Brand acquisitions include Myonal and Merislon in 9 markets, Bayer’s Meliane in 30 markets, and Roche Pharma’s Rocephin in 80 markets.
Priorities are extending the global platform, strengthening launch capabilities, and expanding in-licensed and own-brand portfolios.
Latest events from DKSH
- Core EBIT grew 12.6% at CER as margin reached 3.0% and free cash flow hit CHF 282.3 million.DKSH
H2 2023 - NewBridge extends healthcare into MENA and is expected to be accretive from closing.DKSH
M&A announcement - EPS up 18.2%, Core EBIT up 3.6%, and strong cash flow highlight robust H1 2026.DKSH
H1 2026 - Core EBIT up 6.7% to CHF 349m, margin expands, and dividend rises 6.4% amid strong cash flow.DKSH
H2 2025 - Net sales and core EBIT rose, margins expanded, and M&A activity remained strong in H1 2025.DKSH
H1 2025 - Accelerated growth, margin expansion, and impactful M&A drive a robust midterm outlook.DKSH
CMD 2024 - Core EBIT up 8.2% at CER, net sales up 3.3% at CER, strong cash flow and margin expansion.DKSH
H1 2024 - Core EBIT up 8.4% at CER, margin expands to 3.1%, and 2025 outlook remains positive.DKSH
H2 2024